title: Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin).
authors.forename: Focke
authors.initials: F
authors.lastname: Ziemssen
authors.forename: Christoph M
authors.initials: CM
authors.lastname: Deuter
authors.forename: Nicole
authors.initials: N
authors.lastname: Stuebiger
authors.forename: Manfred
authors.initials: M
authors.lastname: Zierhut
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014605:Uveitis / Q000150:complications*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab